BioSpace News Archive

Allogene Therapeutics, Inc. today announced that it will report fourth quarter and year-end 2021 financial results on Wednesday, February 23, 2022 after the close of the market.

Organon announced that it has acquired the rights from Bayer AG to Marvelon® and Mercilon®, combined oral hormonal daily contraceptive pills, in the People’s Republic of China, including Hong Kong and Macau, and has entered into an agreement to acquire the rights to these products in Vietnam.

Predicine, a global molecular insights company, announced today that it will present six posters highlighting clinical utility of Predicine’s full suite of liquid- and tissue-based comprehensive genomic profiling solutions at the ASCO Genitourinary Cancers Symposium being held February 17-19, 2022, in San Francisco.

T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced the execution of territory exclusive distribution agreements in Norway, Finland, and Türkiye.

Endonovo Therapeutics Inc. (OTC-ENDV) an Innovative Medical Devices developer and distributor is pleased to announce it has filed a Regulation A+ financing for expansion of their operations and has retained Dalmore Group (“Dalmore”), a veteran industry leading broker-dealer to provide operations and compliance services in the completion of this Regulation A+ and its anticipated subsequent Reg A+ offering.

ImmunoScape, today announced that it has signed a licensing deal with Pure MHC, LLC, a target discovery and development company, to pursue TCR-T therapeutics against Pure MHC-identified antigens in lung cancer, colorectal cancer, and other cancer indications.

Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), today announced the closing of its previously announced registered direct offering, whereby a single accredited institutional investor purchased approximately $10 million of the Company’s common stock and pre-funded warrants, as well as warrants to purchase common stock in a concurrent private placement.

Genmab A/S announced the publication of its Annual Report for 2021.

Likarda’s Custom Hydrogel Encapsulant to be Used as Cell Therapy Delivery System to Treat Equine Lameness.

The report offers detailed overview of the market with recent market dynamics and industrial status. The report provides details about market size, market restraints, drivers, challenges, growth opportunities, and top companies in the market.